Á lódáil...
Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18
BACKGROUND: Liposomal doxorubicin (Doxil) is a cytotoxic chemotherapy drug with a favorable hematologic toxicity profile. Its active drug, doxorubicin, has interesting immunomodulatory properties. Here, the effects of Doxil on surviving tumor cell immunophenotype were investigated. METHODS: Using ID...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
BioMed Central
2009
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2797002/ https://ncbi.nlm.nih.gov/pubmed/20003308 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-7-104 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|